To proteomic analysis Prior, a CSF sample may need to be further processed by desalting, prefractionation, dialysis, ultrafiltration,63 depletion of high-abundance proteins (e.g., albumin and immunoglobulin), and protein precipitation (with acetone and/or trichloroacetic acid).61 These are carried out to enrich and thereby improve identification and quantification of protein biomarkers, which may otherwise be present in scarce amounts or masked by abundant proteins, and to eliminate salts ( 150 mmol/L), which may interfere with electrophoretic analysis. Methodologies for Data Acquisition and Processing Two major and complementary methodologies are widely utilized for downstream quantitative protein and peptide analysis in glioma proteomics research (Fig.?1). In the past decade, differential proteomic profiling techniques have utilized tumor, cerebrospinal fluid, and plasma from glioma patients to identify the first candidate diagnostic, prognostic, predictive, and therapeutic response markers, highlighting the potential for glioma biomarker discovery. The number of markers identified, however, has been limited, their reproducibility between studies is usually unclear, and none have been validated for clinical use. Recent technological advancements in methodologies for high-throughput profiling, which provide easy access, rapid screening, low sample consumption, and accurate protein identification, are anticipated to accelerate brain tumor biomarker discovery. Reliable tools for biomarker verification forecast translation of the biomarkers into clinical diagnostics in the foreseeable future. Herein we update the reader around the recent trends and directions in glioma proteomics, including key findings and established and emerging technologies for analysis, together with challenges we are still facing in identifying and verifying potential glioma biomarkers. = 11) vs. GBM (= 12)2DEIdentified 22 upregulated proteins, including oncoprotein 18, nucleoside diphosphate kinase A, GSTP, and moesin2Zhang et al. 200398Cell lines: fetal human astrocytes (FHA), U87MG, U87MGEGFR2DE, LC-MS-MS, MALDI-TOF MS23 and 29 proteins were expressed exclusively Epipregnanolone in FHA and U87MG, respectively; 3 proteins were upregulated in U87MGEGFR relative to U87MG: ubiquitin, cystatin B, TTG4 Hbb-bh1 proteins (Hsp27, major vault protein, TTG, and cystatin B) were further verified3Hiratsuka et al. 200399Biopsies: gliomas, grades II and III and GBM; nontumoral Epipregnanolone tissue2DE11 proteins were upregulated in gliomas: CRMP4, albumin, hemopexin, copine I, prohibitin, phosphoserine phosphatase, TTR, apoliprotein A-1, catechol-O-methyltransferase, fatty acid binding protein 7, and neurocalcin ; 4 were downregulated in gliomas: SIRT2, profilin-2, UCH-L1, and PEA-15SIRT2 was further verified4Zheng et al. 200326CSF: OD (= 2), AOD (= 3), AOA (= 2), PA (= 2), GBM (= 1), medulloblastomas (= 2) vs. normal controls (= 14)2DE, MALDI-TOF MSIdentified 2 proteins that were found in primary brain tumors, but absent in controls, including N-myc and caldesmon (l-CaD); l-CaD was, in addition, absent in medulloblastomas samplesN-myc and l-CaD were further verified by IHC5Hobbs et al. 2003100Biopsies: GBMSELDI-TOF MSIdentified Epipregnanolone a panel of proteomic profiles from radiographically distinct regions of a tumor6Furata et al. 200430Biopsies (= 30): A (= 5), AA (= 2), GBM (= 13: 6 primary, 7 secondary)2DE, NanoLC-MS/MSIdentified the following differentially expressed proteins in primary GBM: tenascin precursor, enolase-1, centrosome associated protein 350, EGFR; in secondary GBM: ERCC6, DUOX2, Wnt-11 precursor, cadherin-related tumor suppressor homolog precursor, ADAMTS-19, and hnRNP A37Schwarts et al. 200431Biopsies (= 20): gliomas, Epipregnanolone grade II (= 3), grade III (= 3), GBM (= 4) vs. normal controls (= 5)MALDI-MSUtilized MALDI for direct proteomic tissue profiling8Iwadate et al. 200429Biopsies (= 85): A (= 10), AA (= 13), GBM (52) and normal brain tissues (= 10)2DE, MALDI-TOF MSIdentified 37 differentially expressed proteins between low- and high-grade astrocytomas, including nucleolar GTP-binding protein, glutamate dehydrogenase, and CREB-1CREB-1, Rac1, RhoA, and enolase were verified further by IHC9Chumbalkar et al. 200541Biopsies (= 27): A, grade I (= 2), A (= Epipregnanolone 1), AA (= 14), and GBM (= 10)2DE, MALDI-TOFIdentified 72 differentially expressed proteins in grade-specific manner. 29 of these were short-listed, including Rho-GDI, prohibitin, GFAP, HSP60, HSP70, vimentin, and -crystallinProhibitin and GFAP were further verified by WB10Liu et al. 200514Serum (= 105): A, grades I, II, III and GBM, nontumoral controlsSELDI-TOF-MSProvided an extensive bioinformatic analysis of nontumoral controls vs. GBM, and of low vs.high A grades11Iwadate et al. 200540Biopsies (= 93); response to cytotoxic drugs2DE, MALDI-TOF MSIdentified a list of 41 proteins that significantly affected the in vitro chemosensitivity to each category of anticancer brokers tested12Vogel et al. 200555Biopsies and cell lines: U87, U251, U118, A172 compared with GBM biopsies (= 8)2DEIdentified 220 differentially expressed proteins, including DNA polymerase -catalytic subunit A, hHYD, LRP-1, CAPG, AKAP-9, Calgizzarin, Anx, LASP-1, PDI, PKM1/2, S100A6, GFAP13Odreman et al. 200538Biopsies: fibrillary A, grade II (= 10) – GBM (= 10)2DE, LC-ESI-MS-MSIdentified 15 differentially expressed proteins, including peroxiredoxin 1/6, -internexin, BTF3, PDI A3, UCHL1, PKA14Schwartz et al. 200537Biopsies (= 162) and cell line: nontumoral controls (= 19), grade II (= 29), grade III (= 22), GBM (= 57), and U118MG cell line2D-LC, MALDI MS-MS, MALDI ESI-ITIdentified 6 potential biomarkers, including calcyclin, calpactin I light chain, tubuline-specific chaperone A, astrocytic phosphoprotein PEA 15, fatty acid binding protein 5Dynein light chain 2 and calcyclin discriminated between 2 survivor groups15Wang et al. 200539Biopsies (= 1): GBM (= 1)cIEF, ESI MS-MSIdentified 1820 unique proteins, including.